期刊文献+

HC-1119对三阴性乳腺癌BT549细胞生物学行为的影响 被引量:2

Effect of HC-1119 on biological behaviors of triple-negative breast cancer BT549 cells
下载PDF
导出
摘要 目的:检测新型人工合成的雄激素受体(androgen receptor,AR)拮抗剂HC-1119对三阴性乳腺癌BT549细胞生物学功能的影响,并探讨其分子机制。方法:用Western blot法检测不同人乳腺癌细胞系MDA-MB-231、T47D、MCF-7、SKBR3和BT549中AR的表达。在AR表达阳性的三阴性乳腺癌BT549细胞中,采用HC-1119进行刺激,用CCK-8法检测细胞活力;流式细胞术检测细胞凋亡和周期分布情况,Transwell实验检测细胞迁移和侵袭情况,Western blot法检测HC-1119刺激对BT549细胞中E-cadherin、vimentin和P21表达的影响。结果:AR在BT549细胞中阳性表达;HC-1119呈浓度和时间依赖性抑制BT549细胞的活力(P<0.05),显著上调BT549细胞的早期凋亡百分比和S期百分比(P<0.01),抑制BT549细胞的迁移和侵袭能力(P<0.05);此外,HC-1119还能抑制BT549细胞中P21表达(P<0.01),而E-cadherin和vimentin的表达未见改变。结论:AR拮抗剂HC-1119能够抑制AR阳性的三阴性乳腺癌BT549细胞的活力、迁移能力和侵袭能力,促进细胞凋亡,阻滞细胞周期;HC-1119通过P21调节细胞生长,却没有经过上皮-间充质转化而参与BT549细胞的迁移行为。 AIM:To explore the effect of new artificially synthesized androgen receptor(AR)antagonist HC-1119 on the biological function of triple-negative breast cancer(TNBC)BT549 cells and the molecular mechanism.METHODS:The AR expression was assessed in different human breast cancer cell lines MDA-MB-231,T47D,MCF-7,SKBR3 and BT549 by Western blot.The TNBC BT549 cells with AR positive expression were treated with HC-1119.The cell viability was measured by CCK-8 assay.The apoptosis rate and cell cycle distribution were analyzed by flow cytometry.The migration and invasion abilities were detected by Transwell assay in vitro.The protein expression of E-cadherin,vimentin and P21 was determined by Western blot.RESULTS:AR was positively expressed in BT549 cells.HC-1119 inhibited the cell viability in a time-and dose-dependent manner(P<0.05),increased the percentage of apoptotic cells and the percentage of S-phase cells significantly,repressed the migration and invasion abilities(P<0.05),and decreased P21 expression at protein level(P<0.01).No influence on the expression of E-cadherin and vimentin in the BT549 cells was observed.CONCLUSION:AR antagonist HC-1119 decreases the viability,migration ability and invasion ability,enhances the apoptosis,and arrests the cell cycle distribution of TNBC BT549 cells.HC-1119 represses the viability of BT549 cells by down-regulating P21 expression,while the process of epithelial-mesenchymal transition is not involved in the inhibition of cell migration.
作者 黄钱 任秋宇 张春燕 何涛 甘淋 HUANG Qian;REN Qiu-yu;ZHANG Chun-yan;HE Tao;GAN Lin(Department of Biochemistry and Molecular Biology,Southwest Medical University,Luzhou 646000,China;Institution for Cancer Medicine,College of Basic Medical Sciences,Southwest Medical University,Luzhou 646000,China)
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2019年第12期2221-2226,共6页 Chinese Journal of Pathophysiology
基金 四川省科技厅国际合作项目(No.2018GJHZ0249) 泸州-西南医大联合项目(No.2017LZXNYD-J11)
关键词 三阴性乳腺癌 雄激素受体 HC-1119 细胞活力 细胞凋亡 Triple-negative breast cancer Androgen receptor HC-1119 Cell viability Apoptosis
  • 相关文献

参考文献1

二级参考文献11

  • 1Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J]. JAMA, 2006, 295 (21): 2492-2502.
  • 2Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J]. J Clin Oncol, 1999,17:1474-1481.
  • 3Kaaks R, Rinaldi S, Key T J, et al. Postmenopausal serum androgens, oestrogens and breasf cancer risk: the European prospective investigation into cancer and nutrition [J]. Endocr Rerat Cancer, 2005,12 (4): 1071-1082.
  • 4Tworoger SS, Missmer SA, Eliassen AH, et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women [J]. Cancer Epidemiol Biomarkers Prev, 2006,15 (5):967-971.
  • 5Wong YC, Xie B. The role of androgens in mammary carcinogenesis [J]. Ital J Anat Embryol, 2001,106(2 Suppl 1):111-125.
  • 6Bryan RM, Mercer R J, Bennett RC, et al. Androgen receptors in breast cancer [J]. Cancer, 1984,54:2436-2440.
  • 7Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations [J]. Am J Clin Pathol, 2003, 120 (5):725- 731.
  • 8Gonzalez LO, Cortel MD, Vazquez J, et al. Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloprotenases and their inhibitors [J]. BMC Cancer, 2008,8:149.
  • 9Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters [J]. Eur J Cancer, 1996, 32A(9): 1560-1565.
  • 10Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors [J]. J Pathal, 1993,170(1 ):31-35.

共引文献20

同被引文献6

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部